ANTI-MUTANT CALRETICULIN ANTIBODIES AND THEIR USE IN THE DIAGNOSIS AND THERAPY OF MYELOID MALIGNANCIES

摘要

The present invention relates to an antibody that specifically binds to a mutant calreticulin protein, wherein the variable region of the heavy chain of said antibody comprises a CDR-H3 region having an amino acid sequence as depicted in SEQ ID NO.: 3, or a CDR sequence having 75% or more amino acid identity to said CDR; or wherein the variable region of the heavy chain of said antibody comprises a CDR-H3 region having an amino acid sequence as depicted in SEQ ID NO.: 6, or a CDR sequence having 75% or more amino acid identity to said CDR. Hybridoma 8B2-H6-10.7 deposited under accession number DSM ACC3249 with the depositary institute DSMZ on Sep. 12, 2014 as well as antibodies obtainable therefrom are subject of the present invention. The antibodies provided herein can be used in the diagnosis of or therapeutic intervention in myeloid malignancies.